Notice of Intent to Sole Source: Promega Reagent Kits and Assays

Closed Special Notice Posted

Solicitation number
75N95024Q00394
Agency
Responses due
Set-aside
No set-aside

Opportunity facts

Notice details come from SAM.gov. Updated .

About this opportunity

The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA) and the National Center for Advancing Translational Sciences (NCATS) have issued a Special Notice to award a sole source contract to Promega Corporation for the procurement of Promega reagent kits and assays. This procurement is being conducted under simplified acquisition procedures and is exempt from full and open competition requirements.

The purpose of this procurement is to acquire Promega reagent kits and assays for NCATS' Antiviral Program for Pandemics. The essential product requirements include reagents that are easily scalable, highly sensitive, and optimized for high-throughput screening, secondary screening, and lead optimization. The estimated period of performance is 30 days. Interested parties may submit capability statements, proposals, or quotations, which the government will consider in determining whether to proceed on a non-competitive basis or conduct a competitive procurement. Responses should include unit pricing, delivery timeframes, and other pertinent information. All offerors must have an active registration in the System for Award Management (SAM).

Notice text

INTRODUCTION

THIS IS A PRE-SOLICITATION NON-COMPETITIVE (NOTICE OF INTENT) SYNOPSIS TO AWARD A CONTRACT WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).

The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA) the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to Promega Corporation 2800 Woods Hollow Rd Madison, WI 53711 forPromega Reagent Kits and Assays.

NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE and SET ASIDE STATUS

The intended procurement is classified under NAICS 325414 Research and Development in Biotechnology with a Size Standard of 1,250.  

REGULATORY AUTHORITY

This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures. Contracts awarded using FAR Part 13—Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6—Competition Requirements. FAR Subpart 13.106-1 (b) Soliciting from a single source provides that: For purchases not exceeding the simplified acquisition threshold, Contracting officers may solicit from one source IF the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, brand-name OR industrial mobilization).

The resultant contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2022-08 dated October 22, 2022.

DESCRIPTION OF REQUIREMENT

PURPOSE AND OBJECTIVES:

The purpose of this procurement is the acquisition of Promega reagent kits and assays for the Antiviral Program for Pandemics at NCATS.

Purchase Description:

Promega manufactures a number of reagent systems that NCATS uses in multiple ongoing assays and projects. These assay systems and kits allow NCATS to measure specific outcomes of cells. Their products are specifically engineered for high throughput and automation settings- the standard at NCATS.

Essential features:

-           All reagents must be easily scalable and highly sensitive

-           Reagent kits and assays must be optimized for Primary high-throughput screening, secondary screening and lead optimization.

-           Engineered for live cell imaging

-           Optimized for multiwell plates and automation equipment

-           Easily scalable

Cat. #  Qty      Description

V7603X           5          MTase-Glo(TM) Methyltransferase Assay

Each V7603X kit includes:

•           10 x A120C SAM, 1mM, 1ml

•           10 x A233B SAH, 15uM, 0.3ml

•           1 x V760X MTase-Glo™ Reagent, 10X, 50ml

•           1 x V761X MTase-Glo™ Detection Solution, 500ml

ESTIMATED PERIOD OF PERFORMANCE:

30 Days ARO

CONTRACTING WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME) DETERMINATION

The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted. Specifically, Promega Corporation 2800 Woods Hollow Rd Madison, WI 53711 is the only vendor in the marketplace that can provide the services required by NIDA .

The intended source is:

Promega Corporation 2800 Woods Hollow Rd Madison, WI 53711

CLOSING STATEMENT

THIS SYNOPSIS IS NOT A REQUEST FOR COMPETITIVE PROPOSALS. However, interested parties may identify their interest and capability to respond to this notice.

A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. All responsible sources may submit a capability statement, proposal, or quotation which shall be considered by the agency. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement.

Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Unique Entity ID (UEI), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov.

All responses must be received by the closing date and time of this announcement and must reference the solicitation number, 75N95024Q00394. Responses must be submitted electronically to Kaitlyn Landi, Contract Specialist, at kaitlyn.landi@nih.gov and KJ Shaikh, Contracting Officer, at kj.shaikh@nih.gov.  U.S. Mail and fax responses will not be accepted.

Files

File Type Posted
B NOTICE OF INTENT to Sole Source.docx DOCX document

Similar open opportunities

Opportunity Agency Set-aside Responses due
Synthesis and Distribution of Drugs of Abuse and Related Compounds NAICS 541715 National Institute on Drug Abuse No set-aside
Synthesis and Distribution of Drugs of Abuse and Related Compounds NAICS 541715 National Institute on Drug Abuse Total Small Business
Sirturo (Bedaquiline) tablets for the NIH (Notice of Intent to sole source) Bethesda, Maryland 20814, United States · NAICS 325412 NIH Clinical Center No set-aside
RNA sequencing and whole genome sequencing services Bethesda, Maryland 20892, United States · NAICS 32599 Office of Logisitics and Acquisition Operations No set-aside
Stability Testing for ManNAc Drug Product produced in Campaigns 5 and 6. Stability testing will occur under regulatory compliance Bethesda, Maryland 20892, United States · NAICS 541380 Office of Logisitics and Acquisition Operations No set-aside

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors